Nivolumab or Pembrolizumab for Metastatic Cancer
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 264 (estimated)
- Sponsor
- University of Chicago · Other
This trial is looking for patients with advanced or metastatic cancer to compare how often they can receive treatment with nivolumab or pembrolizumab. Participants will have their blood tested to see how the drug levels compare with different dosing schedules.
You may be able to join if
- I have locally advanced or metastatic cancer.
- I am 18 years old or older.
- My doctor says I can be treated with nivolumab or pembrolizumab.
- I have measurable disease.
You may not be able to join if
- I have previously received immune checkpoint inhibitors.
- I have received investigational monoclonal antibody therapy.
- My treatment plan includes ipilimumab.
- I am receiving nivolumab and ipilimumab together.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityA randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.
Loading trial locations…